Background The burden of hepatitis B virus (HBV) infection in China is high. The safety and
efficacy of secukinumab in psoriasis patients with HBV infection have not been fully …

Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The
aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C …

Abstract Background and Objective Biologics for psoriasis, especially anti-tumor necrosis
factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) …

The case reported describes a 48-year-old man with congenital hepatitis B receiving
secukinumab for treatment of psoriasis. Some biologic therapies have been associated with …

Background The efficacy and safety of secukinumab in psoriasis patients has been
demonstrated in randomized controlled clinical trials. Objectives The authors aimed to …

Abstract Introduction Plaque psoriasis (PsO), characterized by demarcated, erythematous,
scaly skin, can have a substantial negative impact on patients' quality of life. This …

Purpose: Biologic therapy in psoriatic patients with multiple comorbidities is challenging due
to worsening of associated diseases and possible side effects of concomitant medications …

Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Background: Secukinumab is a fully human monoclonal antibody that neutralizes interleukin-
17A (IL-17A), a key cytokine involved in the development of psoriasis. Here, we …